Salmonella Enteritidis lipopolysaccharide O:9 O-antigen polysaccharide (O:9 O-antigen)

The Salmonella Enteritidis lipopolysaccharide O:9 O-antigen polysaccharide is a critical surface component of the Gram-negative bacterium Salmonella enterica serovar Enteritidis (Gasperini et al., 2024). It consists of a repeating oligosaccharide unit composed of mannose, rhamnose, and galactose, with a unique tyvelose side chain that defines the O:9 serogroup specificity (Reeves et al., 2013). Biologically, this polysaccharide is essential for the structural integrity of the bacterial outer membrane and serves as a primary defense mechanism against the host immune system by providing resistance to complement-mediated killing (Krzyżewska-Dudek et al., 2024). It also plays a role in environmental persistence and biofilm formation, which are vital for the pathogen's transmission cycle (Guard-Bouldin et al., 2004). In a clinical context, the O:9 O-antigen is a major therapeutic target for the development of vaccines against invasive nontyphoidal salmonellosis (iNTS), a condition with high mortality rates in sub-Saharan Africa (Rossi et al., 2025). Current vaccine strategies, such as glycoconjugates and Generalized Modules for Membrane Antigens (GMMA), utilize this antigen to elicit high titers of bactericidal and opsonizing antibodies (Gasperini et al., 2024). These antibodies facilitate the clearance of the bacteria through the classical complement pathway and phagocytic uptake (Simon et al., 2011). Beyond its role as a vaccine target, the O:9 antigen is used as a diagnostic biomarker for serotyping Salmonella isolates and monitoring vaccine efficacy in clinical trials (Rossi et al., 2025).

Other names

Salmonella Enteritidis O-antigenO:9 polysaccharideSalmonella Group D O-antigenSE O-antigenO-polysaccharide (OPS)O-antigen capsule

Induction of bactericidal and opsonizing antibodies that mediate complement-dependent killing and phagocytosis of the bacteria (Gasperini et al., 2024; Rossi et al., 2025).